Janux Therapeutics Partners with Bristol Myers Squibb in Major Cancer Drug Deal
Janux Therapeutics announces collaboration with Bristol Myers Squibb to develop novel tumor-activated cancer therapy, with potential payments up to $850 million.
Janux Therapeutics announces collaboration with Bristol Myers Squibb to develop novel tumor-activated cancer therapy, with potential payments up to $850 million.
Janux Therapeutics' (JANX) JANX007 immunotherapy disappoints with only 30% response rate in heavily pre-treated prostate cancer patients, raising concerns about efficacy.